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Introduction
Accelerated vein graft atherosclerosis remains a major limiting factor in the successful treatment of occlusive arterial disease, and attempts to date at improving longterm autologous vein graft patency with various pharmacotherapeutic agents have failed. 1, 2 While the neointimal hyperplasia that occurs in all vein grafts helps to achieve mechanical stability in these otherwise thin-walled conduits, it is believed that this neointima serves as the substrate for the development of atherosclerotic disease. Up to 50% of vein bypass grafts fail within a period of 10 years as a result of this occlusive disease, [3] [4] [5] whereas high patency rates are maintained for periods exceeding 15 years when arterial vessels without significant neointima are used as bypass grafts. 6 This process involves formation of a neointimal layer of vascular smooth muscle cells (VSMC) that is highly susceptible to accelerated atherosclerosis, 4, 6 since vein grafts respond to two major stimuli: (1) injury due to manipulation and ischemia at the time of surgery; and (2) increased intraluminal pressure and shear stress exerted on the venous wall by the arterial environment. Injury to the vessel wall promotes neointimal formation in arteries as well as veins. [7] [8] [9] Neointimal hyperplasia after vein grafting as well as angioplasty involves many growth factors including thrombin, fibroblast growth factor (FGF), and plateletderived growth factor (PDGF) which activate cell cycle progression. [10] [11] [12] [13] [14] Since cyclin was first discovered, it has become clear that cell growth is dependent on the coordinated actions of cell cycle regulatory genes. [15] [16] [17] [18] Previously, we observed an increased gene expression of cell cycle regulatory genes in balloon-injured rat carotid arteries. 19, 20 Accumulating observations in vascular biology clearly demonstrate the importance of the retinoblastoma (Rb) gene product and tumor suppressor gene p53 in controlling VSMC cell cycle progression. [15] [16] [17] [18] 21, 22 More recently, p21, also known as Cip1 (CDK-interacting protein), sdi-1 (senescent cell-derived inhibitor), and WAF1 (wild-type p53-activated fragment), has been reported to be an important inhibitor of cell cycle progression in fibroblasts and also plays a critical role in protecting cells against certain types of injury. [23] [24] [25] Previously, researchers have speculated that genetic engineering may improve the long-term function of vascular vein grafts which are prone to atherosclerosis and occlusion. We therefore applied a gene therapy strategy using p21 (sdi-1) gene to prevent neointimal formation in a rabbit vein graft model by using a hemagglutinating virus of Japan (HVJ) liposome. Interestingly, these genetically modified grafts demonstrated a marker of the adult phenotype of VSMC that was not seen in control grafts.
Results
We examined the effects of in vivo transfer of the human sdi-1 gene to rabbit vein graft model on neointimal formation. Successful transfer of the sdi-1 gene by intraluminal incubation with HVJ-liposome complex was confirmed by Western blotting of the protein of sdi-1 (Figure 1 ). In sdi-1 vector-transfected vessels, the existence of sdi-1 protein identical to the molecular size as previously reported could be detected by Western blotting. In contrast, no apparent band could be observed in control vector-transfected vessels. We first studied the effects of transfer of sdi-1 vector on vascular DNA synthesis assessed by PCNA staining and neointimal thickness (2 weeks after vein grafting). Transfection of sdi-1 vector significantly decreased PCNA-stained VSMC (a marker of DNA synthesis) in the medial and neointimal areas 14 days after vein grafting as compared with the control vectortransfected controls (P Ͻ 0.01) (Figure 2a and b) . In intact normal vessels, less than 1% of the cells in the tunica media stained positively for PCNA by immunohistochemical technique (data not shown). Neointimal formation was assessed by morphometric analysis of perfusionfixed specimens 14 days after vein grafting in a blinded fashion. Transfection of sdi-1 vector also inhibited neointimal formation by approximately 70% (n = 7) compared with untreated grafts (n = 5) and control vector transfected grafts (n = 8) (Figure 3 ). Consistent with in vivo results, in vitro experiments also revealed that transfection of human p21 vector resulted in a significant inhibition of rabbit and human VSMC stimulated by serum (data not shown).
It is noteworthy that in vivo transfer of the sdi-1 gene did not completely suppress neointimal formation. Given the previous report that the inhibition of neointimal formation in a vein graft model by antisense oligonucleotides (ODN) directed against cdc 2 kinase and PCNA resulted in resistance to atherosclerosis, 26 we postulated that manipulation of cell cycle progression would alter vascular phenotype. To address this question, we determined the phenotype of VSMC according to the expression pattern of myosin heavy chain (MHC) isoforms, SM2 and SMemb; SM2 exists only in the adult, and SMemb only in the embryo. The medial VSMC of normal veins or vein grafts before implantation stained positively for SM2 and negatively for SMemb, indicating adult-type VSMC. Of importance, in vivo transfer of sdi-1 vector showed the change of VSMC phenotype from neonatal to adult, assessed by imunohistochemical detection of myosin heavy chain subtypes ( Figure 4 ). Figure 4 demonstrates the typical immunohistochemical pattern of the control vector-and sdi-1 vector-transfected grafts at 14 days after transfection. In control vector-transfected grafts, the neointima was formed predominantly with embryonic phenotype of VSMC, which stained negatively for SM2 but positively for SMemb. Untransfected grafts showed hardly any staining for SM2 in the formed neointima (data not shown). On the other hand, in the majority of sdi-1 vector-transfected grafts, SM2 protein could be detected throughout the intimal thickness of the vessels, while the staining for SMemb was not changed, demonstrating the predominant expression of the adult phenotype of VSMC in grafts transfected with the human sdi-1 gene. Nonimmune immunoglobulin IgG did not result in nonspecific staining in either transfected or untransfected vessels. These results indicate that the sdi-1 gene treatment induced expression of adult phenotype of VSMC in the formed neointima, which is less 'synthetic' and closer to the normal vessel components.
Discussion
One of the important diseases potentially amenable to gene therapy is coronary artery disease, as well as restenosis after angioplasty, since the long-term effectiveness of this procedure is limited by the development of restenosis in over 40% of patients. [1] [2] [3] [4] [5] 10 Neointimal formation after bypass grafting or angioplasty involves a complex interaction between multiple growth factors that promote VSMC proliferation and migration. [10] [11] [12] [13] [14] Therefore, it appears unlikely that selective inhibition of a particular growth factor will completely prevent lesion formation. Accordingly, we hypothesize that restenosis could be prevented by the blockade of genes regulating cell cycle progression -the final common pathway. In our previous study, we reported that the inhibition of cell cycle regulatory genes such as cdk 2 kinase resulted in inhibition of neointimal formation after vascular injury. 19, 20 This strategy is also very effective in the prevention of neointimal formation after vein grafting, as previously reported. 26 In this study, we postulate that the sdi-1 gene may be an ideal target for overexpression in the vein graft model. In a balloon injury model, Chang et al 27 reported that in vivo transfection of the sdi-1 gene resulted in the inhibition of neointimal formation, but there is no report on the efficacy of this strategy in a vein graft model. Recent studies have shown that sdi-1 inhibits a complex of cdk kinases and cyclins which plays a pivotal role in the progression of the cell cycle. [15] [16] [17] [18] In addition to its ability to inhibit kinase activities of cyclin-CDK complexes, sdi-1 has also been reported to bind to, and to inhibit the activity of, the DNA polymerase ␦ co-factor, PCNA ( Figure 5) . [23] [24] [25] 28 We therefore tested the hypothesis that overexpression of the sdi-1 gene would result in the inhibition of neointimal formation in a rabbit vein graft model.
Our present study demonstrated the increased protein level of sdi-1 at 7 days after transfection in vivo. The increase in PCNA-positive cells was abolished by intraluminal administration of sdi-1 vector. A single administration of sdi-1 vector also resulted in a significant reduction of neointimal formation at 14 days after transfection. These results are consistent with the previous report that transfection of antisense ODN against PCNA and cdc 2 kinase resulted in the inhibition of hyperplasia at 2 weeks after transfection. 26 Indeed, high transfection efficiency of the HVJ-liposome method into blood vessels using balloon injury and vein graft models has been previously reported. 19, 20, 26, [29] [30] [31] [32] Using nuclear-targeted lacZ, Matsumoto et al 29 have reported that transfection of the lacZ gene exhibited diffuse and frequent X-gal-positive signals in both medial and adventitial layers in the vein graft, consistent with the previous report in an organ culture system. 30 Similar results were also obtained using immunohistochemical staining against nitric oxide in grafts transfected with endothelial constitutive nitric oxide synthase. 29, 31 In addition, Yonemitsu et al 32 documented that HVJ liposomes could achieve highly efficient gene transfection into the medial smooth muscle cells of intact arteries at 150 and 760 mmHg of pressure (mean, 85.3% and 93.5% of total smooth muscle cells, respectively) without any inflammatory reaction. Moreover, the sufficient transfection efficiency of the HVJliposome method to inhibit neointimal formation by inhibiting cell cycle progression such as overexpression of p21 was also supported by the previous publications in balloon injury and vein graft models. 19, 20, 26, 31 Moreover, we addressed the following specific question: Is the inhibition of neointimal formation by gene transfer of the sdi-1 gene associated with a change of phenotype? Of importance, increased expression of SM2 protein, whose expression characterizes the adult phenotype of VSMC, [33] [34] [35] [36] [37] [38] was observed in association with the inhibition of cell cycle progression by overexpression of sdi-1. It is recognized that VSMC involved in neointimal hyperplasia undergo a phenotypic change from a contractile to a secretory state, 5 and these 'activated' neointimal VSMC may release interleukin 6, 39 PDGF, 40 or other cytokines that could in turn influence endothelial function and stimulate atherogenesis. As previously reported, expression of the isoform of smooth muscle myosin heavy chain, SM2, could be detected in adult normal vessels (contractile type), whereas it disappeared in ballooninjured vessels, the neointima in vein grafts, and cultured VSMC, thereby indicating a differentiated phenotype. [33] [34] [35] [36] [37] [38] In contrast, expression of SMemb, the embryonic isoform of myosin heavy chain, was mainly expressed in cultured VSMC, balloon-injured vessels, and the neointima in vein grafts, revealing a secretory state. [33] [34] [35] [36] [37] [38] SM1 is constitutively expressed in all types of VSMC. To identify the effects of overexpression of the sdi-1 gene, we studied expression of these three isoforms of myosin heavy chain as a marker of differentiation of VSMC. Our present data first demonstrated the phenotypic modulation of VSMC from embryonic to adult type caused by overexpression of sdi-1. Previous gene transfer experiments showed that the prevention of neointimal formation in the balloon injury model by cell cycle inhibition strategy was sustained long-term over the period of transgene expression or antisense survival. 19, 20, 26 This may relate to the vascular remodeling induced by the inhibition of cell cycle progression. Indeed, administration of antisense PCNA and cdc 2 kinase ODN into a vein graft model altered the resistance to diet-induced atherogenesis. 26 The phenotypic change observed in this study may explain the previous findings. However, the present study failed to address the question: Is phenotypic change directly associated with the overexpression of sdi-1, or is phenotypic modulation a result associated with the inhibition of neointimal formation? Preliminary in vitro experiments showed that transfection of sdi-1 vector resulted in upregulation of SM2, a marker of adult phenotype (unpublished observation). Thus, probably the inhibition of cell cycle progression and neointimal formation by overexpression of sdi-1 may directly modulate VSMC phenotype. A similar observation related to phenotypic change has been reported for TGF-␤1, as TGF-␤1, an inhibitor of cell cycle progression, prevented the loss of smooth-muscle-specific myosin heavy chain, which occurs in primary VSMC culture. 41 Further studies are necessary to dissect out the mechanisms of phenotypic modulation by sdi-1, but one of the possible explanations is the inhibition of phosphorylation of myosin chain which was reported to be controlled by cdc 2 kinase. 42 Alternatively, the close relationship of the cell cycle to myosin is also supported by the observation that a family of cdc, cdc4p, may be a novel myosin light chain. 43 Using an intra-operative system, we successfully prevented neointimal formation in a rabbit vein graft model by overexpression of the sdi-1 gene. More importantly, the inhibition of neointimal formation mediated by p21 was associated with the phenotypic change of VSMC in vivo. We speculate that the inhibition of neointimal hyperplasia by inhibition of the cell cycle may be closely related to re-differentiation of VSMC. We believe that this study is significant for the following reasons: (1) this study provides an important validation of the gene therapy approach in a vein graft model using the sdi-1 gene; (2) our study uses an intraluminal approach in a vein graft model which is more applicable to human therapy than a restenosis model; 17 and (3) our study identifies newer and important aspects of cell cycle inhibition in vascular biology thereby providing a possible explanation for the sustained effect after a single administration reported in previous papers.
Materials and methods

Construction of plasmids
To assess gene transfer efficiency, we utilized a plasmid expression vector containing the sdi-1 gene driven by the SR␣ promoter, as previously described. 23 This expression vector was derived from the plasmid pcDSR␣296 vector (donated by Dr Yoshida, University of Tokyo, Japan). 44 The control vector utilized as a control plasmid in this study did not contain the sdi-1 gene.
Preparation of HVJ-liposome
The preparation of the HVJ-liposome complex has been previously described. 19, 20, 45, 46 Briefly, phosphatidylserine, phosphatidylcholine, and cholesterol were mixed in a weight ratio of 1:4.8:2. The lipid mixture (10 mg) was deposited on the sides of a flask by removal of tetrahydrofuran in a rotary evaporator. Dried lipid was hydrated in 200 l of balanced salt solution (BSS; 137 mm NaCl, 5.4 mm KCl, 13 mm Tris-HCl, pH 7.6) containing DNA-HMG (high mobility group)-1 complex (200 g:64 g), which had previously been incubated at 20°C for 1 h. Liposomes were prepared by shaking and sonication. Purified HVJ (Z strain) was inactivated by UV irradiation (110 erg/mm 2 /s) for 3 min just before use. The liposome suspension (0.5 ml, containing 10 mg of lipid) was mixed with HVJ (35 000 hemagglutinating units) in a total volume of 2 ml of BSS. The mixture was incubated at 4°C for 10 min and then for 30 min with gentle shaking at 37°C. Free HVJ was separated from the HVJ-liposome complex by sucrose density gradient centrifugation. The top layer of the sucrose gradient was collected for use. In this study, we used 35 000 hemagglutinating units for transfection, based on preliminary evidence that varying the concentration of HVJ from 10 000 to 64 000 hemagglutinating units did not result in a significant difference in transfection efficiency. We have previously reported that this preparation method of HVJ-liposome complex for transfection of plasmid DNA into VSMC is highly efficient. 19, 20, 45, 46 Vein graft model and ex vivo transfection New Zealand White rabbits weighing 2.5 to 2.9 kg (Kbl-NZW; Nagano, Japan) fed a standard diet (ORC4 Oriental Yeast Corporation, Osaka, Japan) were used. General anesthesia was induced with xylazine (5 mg/kg, i.m.) and atropine (0.02 mg/kg, i.m.) and maintained with inhalation of 1.2% sevoflurane. Through a midline incision in the ventral area of the neck, the second branch of the external jugular vein was dissected free using the 'no touch' technique. After intravenous injection of heparin (300 units/kg body weight), a vein approximately 30 mm in length was harvested and gently irrigated with heparinized iso-osmotic sodium chloride solution (0.9 g/l) containing papaverine through a 22-gauge catheter inserted in the end. After the other end had been clamped with a hemostatic clip, approximately 500 l of HVJ-liposome complex was infused through the catheter, generating a pressure of approximately 100 mmHg, and the preparation was placed on ice for 20 min according to the previous experimental protocol performed in rat carotid arteries. 19, 20 The incubation temperature at 4°C was set, because it is reportedly suitable for the HVJ-liposome to bind to the cell membrane, 47 as well as for graft preservation. During this period, the right common carotid artery was exposed and dissected. After the scheduled incubation, HVJ-liposome was removed and the graft was interposed in the carotid artery by means of end-toend anastomosis using the cuff technique. 48 This technique achieves anastomosis without suturing the vessels, and thus helps to minimize surgical injury to the vessel wall. The anastomosis was completed by circumferential ligation with 7-0 ligature, and the neck wound was then closed in layers. No adverse neurological or vascular effects were observed in any animal undergoing this procedure. At 7 and 14 days after transfection, the animals were killed.
Procedures were in accordance with the guidelines approved by the Institutional Animal Care and Use Committee, Osaka University Medical School.
Animal harvest and tissue preparation
The grafts were harvested at 7 and 14 days, dissected, briefly rinsed in 0.9% saline solution, and divided into two parts. Half of the specimen was immersion-fixed in methanol-Carnoy's fixative (60% methanol, 30% chloroform, 10% acetic acid) overnight, dehydrated through three changes of methanol and embedded in paraffin. Paraffin sections were stained with hematoxylin eosin as a routine stain or with Elastica van Gieson as an elastin stain, and by immunohistochemical technique as described below. The other half was frozen in OCT compound (Miles Scientific, Naperville, IL, USA) in a cryomold in liquid nitrogen. The other four grafts with the sdi-1 gene or control plasmid treatment were also harvested at 7 days and frozen in liquid nitrogen as a whole tissue before Western blotting analysis.
Immunohistochemical studies
Monoclonal antibodies against smooth muscle specific ␣-actin (1A4; Dako, Glostrup, Denmark) and proliferating cell nuclear antigen (PCNA) (PC-10, Dako) were used as specific markers for VSMC and proliferating cells, respectively, in paraffin-embedded sections. In order to identify the phenotypes of smooth muscle cells, antibodies against MHC isoforms (SM2 and SMemb/NMHC-B) were applied to frozen sections. These MHC isoforms have been demonstrated to be developmentally regulated; 29, 30 SM2 exists only in the adult and SMemb only in the embryo. Thus, SM2 can be considered as a molecular marker for the adult phenotype, whereas SMemb is a marker for the embryonic phenotype. Antibodies against SMemb and SM2 were published previously. 29, 31, 32, 45 Immunohistochemical staining was performed using the immunoperoxidase avidin-biotin complex system with nickel chloride (NiCl) color modification as previously described. 49 Briefly, 3-m sections were deparaffinized, rehydrated before blocking endogenous peroxidase activity with 3% hydrogen peroxidase, and preincubated with 5% normal rabbit serum in Tris-HCl buffered saline (TBS) for 20 min. Diluted primary antibodies (1A4 1:50 and PC-10 1:500) were then applied to sections, and sections were incubated for 30 min. With intervening washing in TBS, they were serially incubated with a 1:400 dilution of biotinylated rabbit, antimouse IgG (Dako) in TBS for 30 min; streptavidin-biotinylated horseradish peroxidase complex (Dako), diluted 1:100 in TBS for 30 min; 0.05% 3,3Ј-diaminobenzidine (DAB; Sigma Chemicals, St Louis, MO, USA) in 200 ml TBS to which had been added 0.2 ml 30% hydrogen peroxide and 1.0 ml 8% NiCl solution for 10 min. Sections were counterstained with methylgreen, dehydrated in a graded series of alcohol concentrations, permeated with xylene, and then covered with a coverslip. Frozen sections, approximately 3 m in thickness, were cut from fresh-frozen blocks of tissue and used for immunostaining for SM2 and SMemb. Since fixation affects the sensitivity of immunostaining, no fixation was used. The primary antibodies were diluted 1:1000, and biotinylated rabbit, antimouse (Fab) 2 (Dako) with 1:400 dilution was applied as the second antibody.
Quantification of cell proliferation in intimal lesions
The paraffin-embedded sections of the grafts harvested at 14 days after transfection were used for quantification of cell proliferation. Four sections of each vessel spaced at 0.4-mm intervals were measured by computerized image analyzer system (Image Command 5098; Olympus, Tokyo, Japan). The number of PCNA-positive nuclei and of methylgreen-positive nuclei were counted in the intima by image analyzer system at × 400 magnification. Frequency of cell proliferation was expressed as PCNA index, defined as the ratio of the number of PCNA-positive nuclei to that of all the nuclei in the media. 49 Samples were coded so that the analysis was performed without knowledge of which treatment each individual vessels had received. The reproducibility of the results was assessed. Intra-observer variability was determined from triplicate measurements performed by one observer for all sections. The mean ± s.d. difference among measurements made by the same observer was 2.8 ± 0.5%. Interobserver variability was determined from measurements of 10 randomly selected sections performed by a second observer in addition to the first observer. The difference between measurements made by the two observers was 3.3 ± 0.6%. These observers were blinded to other data concerning the cells, as well as to the results of the other observer. Intimal area was also measured at 0.75 mm intervals by an image analyzer system on the sections with Elastica van Gieson staining of grafts harvested at 14 days after operation. 45 Western blotting of sdi-1 protein in transfected grafts At 7 days after transfection into vein grafts, the vessels were rinsed with PBS, and flash-frozen in liquid nitrogen. A vessel transfected with control vector or sdi-1 vector was incubated in lysis buffer (0.01 m Tris-HCl (pH 7.5), 0.144 m NaCl, 0.5% NP-40, 0.5% SDS, 0.1% aprotinin and 1 mm PMSF) for 30 min on ice. Blots without the primary antibody were performed as a negative control (data not shown). The lysates were centrifuged at 10 000 g for 10 min and subjected to 15% SDS-PAGE at 36 mA for 3 h. Each well was loaded with 20 l (100 g protein) of all lysates. The proteins were transferred to a filter (Bio-Rad, Hercules, CA, USA) overnight at 125 mA. The blots were incubated overnight with anti-sdi-1 monoclonal antibody (at 10 g/ml; Oncogene Science, Cambridge, MA, USA) and then incubated with conjugated secondary antibodies and substrates (Promega, Madison, WI, USA) in conjunction with the ECL chemiluminescence system (Amersham) for detection of bound primary antibody.
Statistical analysis
All values are expressed as mean ± s.e.m. Analysis of variance with subsequent Bonferroni's/Dunnet test was employed to determine the significance of differences in multiple comparisons. Values of P Ͻ 0.05 were considered statistically significant.
